Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 31Lymphoma 18Lymphoma, Large B-Cell, Diffuse 17Sarcoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Neoplasm Metastasis 10Hodgkin Disease 9Lymphoma, Non-Hodgkin 8Recurrence 7Prostatic Neoplasms 7Neoplasms 7Multiple Myeloma 7Burkitt Lymphoma 7Ovarian Neoplasms 6Leukemia 6Lymphoma, B-Cell 5Fallopian Tube Neoplasms 5Cardiotoxicity 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Osteosarcoma 4Liver Neoplasms 4Triple Negative Breast Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Colonic Neoplasms 3Waldenstrom Macroglobulinemia 2

Interventions

Norepinephrine 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Alopecia × Doxorubicin × Clear all
NCT05622058 2023-02-27

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Aileron Therapeutics, Inc.

Phase 1 Terminated
6 enrolled
Breast

Alopecia, Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡